Citation
NIHR HSC. Pertuzumab (Perjeta) for HER2-positive locally advanced, inflammatory or early breast cancer – neo-adjuvant in combination with trastuzumab and docetaxel. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014
MeSH
Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasmss; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids
Address for correspondence
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269 Email: c.packer@bham.ac.uk